Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.

Hotta K, Saeki S, Sakata S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Inoue K, Gemba K, Kubo T, Sato A, Ichihara E, Watanabe H, Kishimoto J, Shioyama Y, Katsui K, Sugio K, Kiura K

Open source

DOI
10.1007/s10147-025-02696-3
Published
2025 Mar
Container
International journal of clinical oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10147-025-02696-3,
  title = {Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.},
  author = {Hotta K and Saeki S and Sakata S and Yamaguchi M and Harada D and Bessho A and Tanaka K and Inoue K and Inoue K and Gemba K and Kubo T and Sato A and Ichihara E and Watanabe H and Kishimoto J and Shioyama Y and Katsui K and Sugio K and Kiura K},
  year = {2025},
  journal = {International journal of clinical oncology},
  doi = {10.1007/s10147-025-02696-3},
  url = {https://doi.org/10.1007/s10147-025-02696-3}
}

RIS

TY  - JOUR
TI  - Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
AU  - Hotta K
AU  - Saeki S
AU  - Sakata S
AU  - Yamaguchi M
AU  - Harada D
AU  - Bessho A
AU  - Tanaka K
AU  - Inoue K
AU  - Inoue K
AU  - Gemba K
AU  - Kubo T
AU  - Sato A
AU  - Ichihara E
AU  - Watanabe H
AU  - Kishimoto J
AU  - Shioyama Y
AU  - Katsui K
AU  - Sugio K
AU  - Kiura K
PY  - 2025
JO  - International journal of clinical oncology
DO  - 10.1007/s10147-025-02696-3
UR  - https://doi.org/10.1007/s10147-025-02696-3
ER  - 

APA

K, H., S, S., S, S., M, Y., D, H., A, B., K, T., K, I., K, I., K, G., T, K., A, S., E, I., H, W., J, K., Y, S., K, K., K, S., & K, K. (2025). Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.. International journal of clinical oncology. https://doi.org/10.1007/s10147-025-02696-3

Source records